Transcript Document
Prospects for Pharmaceuticals:
Selling our Strengths Abroad
Jon Mowles, UKTI Sector Specialist
Japan Society 9th Nov ‘11
Setting the scene
The UK is ranked as the best performer in the G8 leading economies per unit of
R&D spend.
4 of the top 6 rated universities in the world are in the UK viz. Cambridge,
University College London, Imperial College and Oxford.
5 of the top 20 medicines in terms of global sales were developed in the UK.
In the last 10 years Life Sciences departments within UK universities have
generated over 200 spin-out companies, now employing over 1,000 people.
Benefits:
The United Kingdom is a global centre of excellence in Life Sciences where:
–
–
–
–
Innovation is readily commercialised.
People are highly skilled and motivated.
Government is supportive and businesses prosper.
High value given to R&D.
2
Pharmaceutical:
Global FDI - 2006 - 10
Destination
City
No of
Projects
2006-2010
Singapore
39
8%
Shanghai
26
65
6%
Beijing
14
UK
61
6%
Budapest
13
Germany
59
5.5%
Prague
11
Ireland
46
4%
Mumbai
10
Singapore
39
3.5%
France
38
3.5%
Tokyo
10
Russia
35
3%
Dublin
10
Canada
30
2.8%
Sao Paulo
9
Berlin
9
Hyderabad
9
Moscow
9
Destination
Country
No of Projects
2006-2010
% of global
FDI
USA
119
11%
China
85
India
Time Series: January 2006- December 2010
3
Source: fDi Markets™
Pharmaceutical:
UK FDI 2006 - 10
- On average the UK is recipient of 12 Pharmaceutical
projects per annum.
- Motives for UK investment in sector both skilled
workforce and proximity to market were cited as
primary drivers.
- R&D accounted for 39% of Pharmaceutical investment
followed by manufacturing and sales, support &
marketing.
- UK hubs of investment were identified in London,
Cambridge and Scotland.
Attractiveness / Quality of Life
Universities or researchers
Technology or Innovation
Industry Cluster / Critical Mass
Facilities Site or Real Estate
Domestic Market Growth Potential
IPA or Govt support
Infrastructure and logistics
•
Skilled workforce availability
Proximity to markets or customers
0%
5%
10%
15%
20%
TOP UK INVESTORS (2006 – 2010):
Quintiles; Pfizer; Nicholas Piramal India (NPIL);
Amgen; Icon; Warner Chilcott; Kendle
International; Eisai; Intercell; Novartis; Granules
India; Patheon; Clariant; Wyeth; Merck KGaA;
Glenmark Pharmaceuticals; Teva Pharmaceutical
Industries; UCB Group; Sanofi-Aventis; Evotec OAI;
Bilcare
4
Biopharma:
Global FDI - 2006 - 10
Destination
Country
No of Projects
2006-2010
% of global
FDI
USA
79
16%
UK
59
China
Destination
Cities
No of
Projects
20062010
13%
Singapore
23
38
8%
Shanghai
16
India
33
7%
London
12
Germany
29
6%
Boston (MA)
8
Singapore
23
5%
Dubai
7
France
16
3.5%
Beijing
6
Belgium
13
3%
Bangalore
6
Netherlands
12
3%
Dublin
6
Ireland
12
3%
Tokyo
6
Cambridge
6
Time Series: January 2006- December 2010
5
Source: fDi Markets™
Biopharma:
UK FDI 2006 - 10
- On average the UK is recipient of 12
Biotechnology projects per annum.
- Motives for UK investment in sector – 26%
surveyed cited Government support as key
driver.
- R&D accounted for 41% of Biotechnology
investment in the UK 2006-2010. Sales,
marketing and support accounted for 30%.
- UK hubs of investment were identified in
London, Cambridge and Scotland.
Infrastructure and logistics
Industry Cluster / Critical Mass
Finance Incentives or Taxes or Funding
Facilities Site or Real Estate
Domestic Market Growth Potential
Technology or Innovation
•
Skilled workforce availability
Universities or researchers
Proximity to markets or customers
IPA or Govt support
0% 5% 10% 15% 20% 25% 30%
TOP UK INVESTORS (2006 – 2010):
Life Technologies (Invitrogen); SigmaAldrich; Millipore; Genzyme; Pfizer;
Magellan Biosciences; Bioanalytical Systems
(BASi); Bristol-Myers Squibb; ScheringPlough; Wyeth; Serologicals; Waters;
Eurofins Scientific; Cognia; BioMarin
Pharmaceutical; MatriCal; Fziomed;
IdentiGEN; BioGuard Components &
Technologies; MediciNova
6
UK BioPharma Networks
Scotland (Edinburgh, Dundee, Aberdeen)
• Human and animal healthcare
• Environmental biotechnology
• Gene therapy
• Protein engineering
• Combinatorial chemistry
North (Manchester, York, Liverpool, Newcastle)
• Bio-health informatics
• Genomics and Proteomics
• Medical Imaging
• Clinical Genetics
• Bio-manufacturing
• Agricultural/Food Sciences
Cambridge
• Biopharmaceuticals
• Drug discovery-genomics,
• proteomics
• bioinformatics
• combinatorial chemistry
• Protein/DNA sequencing/engineering
• Biomaterials
Northern Ireland
• Diagnostics
• Agriculture
• Veterinary medicine
• Food Sciences
• Environmental
Oxford
• Proteomics
• Genomics
• Chemical libraries
• Vaccines
• Monoclonal antibodies
Wales
• Diagnostics
•Healthcare
• Biotechnology
Surrey
• Agricultural biotechnology
• Production of reagents: cell/tissue cultures
London
• Biopharmaceuticals
• Decoding/transformation of DNA material
• Functions of sub-cellular organisms
• Functional genomics
(Source: UKTI Sector Group, 2007)
7
UKTI: Conclusions
1. Within the Life Sciences Sector, the UK is a good place to do business
2. UK Trade & Investment is the UK Government organisation that:
Helps overseas companies to bring high quality investment to the UK economy.
Helps UK-based companies access international markets to succeed in an
increasingly global economy.
Works with existing foreign investors to grow their business in the UK and
internationally.
A global network. UKTI has staff in British Embassies, High Commissions and
other diplomatic offices around the world.
UK Trade & Investment – Winner 2010: Best Trade Promotion
Organisation in the developed world
UKTI LOOKS TO ADD VALUE!
8
Jon Mowles
Life Sciences Sector Specialist
Investment Directorate - London
UK Trade & Investment
[email protected]
Tel: +44 (0) 7826 912 923
UKTI Website: www.uktradeinvest.gov.uk
9